cardiovascular-risk-factors

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factorsPost-hoc analysis of the EMPA-REG OUTCOME ® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin based on the number of cardiovascular risk factor goals achieved.1Findings from the post-hoc analysis were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes.1  This analysis suggests that, independent of the number of risk factor goals achieved, empagliflozin demonstrated cardiovascular benefits (risk reduction in cardiovascular death, hospitalisation for heart failure and 3P-MACE) in patients with type 2 diabetes and cardiovascular disease that are consistent with primary outcomes from the EMPA-REG OUTCOME ® trial.
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news